- Adherence among chronic disease patients can lead to big savings
- Pfizer forms licensing agreement with Seattle Genetics
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Walgreens allies with HHS to launch free flu shot outreach to disadvantaged
- Medication adherence could be blockbuster for specialty
GUILFORD, Conn. —Mitchell-Vance Labs is in the process of launching a new scar product to add to its ScarAway offering that could appeal to a whole new consumer in search of scar therapy—ScarAway for C-sections.
The therapy may have direct appeal to 1-in-4 new mothers, which is the number of women who give birth by Cesarean section in the United States. According to the March of Dimes, the national weighted average of C-section births is 25.2%, but the percentage of C-sections performed climbs higher than 30% in three states—Mississippi (31.1%), New Jersey (30.9%) and Louisiana (30.4%).
The product features an extended-length, medical-grade silicon scar sheet ideal for placement over C-section cuts.